Wave Life Sciences
56 hedge funds and large institutions have $359M invested in Wave Life Sciences in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 32 increasing their positions, 8 reducing their positions, and 3 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 8
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
14% more funds holding
Funds holding: 49 → 56 (+7)
2.95% more ownership
Funds ownership: 66.74% → 69.68% (+2.9%)
17% less capital invested
Capital invested by funds: $432M → $359M (-$72.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$27.4M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$20.5M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$7.67M |
| 4 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$7.07M |
| 5 |
DM
Deerfield Management
New York
|
+$5.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$6.03M |
| 2 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$4.64M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.59M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$275K |
| 5 |
JP Morgan Chase
New York
|
-$109K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Barclays
London,
United Kingdom
| $15K | +$13.9K | +645 | +345% |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| $13K | +$15.3K | +709 | New |
|
53
Royal Bank of Canada
Toronto,
Ontario, Canada
| $9K | -$2.33K | -108 | -17% |
|
|
PSC
54
Prentiss Smith & Co
Brattleboro,
Vermont
| $9K | – | – | – |
|
55
Bank of America
Charlotte,
North Carolina
| $3K | -$24.1K | -1,116 | -85% |
|
56
Citigroup
New York
| $1K | -$3.96K | -184 | -70% |
|
|
EC
57
EcoR1 Capital
San Francisco,
California
| – | -$275K | -10,000 | Closed |
|
|
58
JP Morgan Chase
New York
| – | -$109K | -3,947 | Closed |
|
|
MAM
59
Meeder Asset Management
Dublin,
Ohio
| – | -$2K | -66 | Closed |
|
WVE Hedge Fund Activity: Q2 2017 in Review
56 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Wave Life Sciences (WVE) for Q2 2017, worth a combined $359M — down 17% from $432M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new WVE positions and 3 closed out — a net gain of 7 holders — while 32 added to existing stakes and 8 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $27.4M. The largest seller was Cormorant Asset Management, cutting an estimated $6.03M.
- 56 institutional investors held Wave Life Sciences (WVE) as of Q2 2017, up from 49 in Q1 2017.
- Funds reported $359M of Wave Life Sciences stock for Q2 2017, down 17% quarter-over-quarter.
- 10 funds opened new Wave Life Sciences positions in Q2 2017 and 3 closed out, a net change of +7 holders.
- The largest Wave Life Sciences buyer in Q2 2017 was T. Rowe Price Associates, an estimated $27.4M added.
- The largest Wave Life Sciences seller in Q2 2017 was Cormorant Asset Management, an estimated $6.03M sold.
Based on aggregated 13F filings for Q2 2017.